The links after "Participants" show which Southwest Oncology Group institutions are eligible to participate in this study.
The orange "Where is This Study Open?" tab at the bottom of the page shows the institutions whose Institutional Review Boards (IRBs) have approved the protocol so that it can be opened at that institution. Clicking on the Institution Name will show the points of contact for information about this study at that institution.
E2496
- Phase III Intergroup(Closed)
Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin’s Disease with 0-2 Risk Factors
Participants:Members, Medical Oncologists, Radiation Oncologists, Pathologists, CCOP
Eligibility Criteria: Previously untreated histologically proven extensive (Stage I-IIA/B) or advanced (Stage III-IV) Hodgkin's disease; >= 16 y.o.; no known HIV; no prior chemo. or RT; WBC >= 4,000/mm3; platelets >= 100,000/mm3; creatinine >= 2.0mg/dl; bilirubin >= 5.0mg/dl; if marrow is involved - hematologic parameters do not apply; ejection fraction recommended for patients >= 50 y.o. with history of cardiac disease.
